- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00777036
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib Therapy in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Cordoba, Argentina, 5016
- Local Institution
-
Cordoba, Argentina, 5016
- Local Institution - 0042
-
-
Buenos Aires
-
Bunos Aires, Buenos Aires, Argentina, 1425
- Local Institution
-
Bunos Aires, Buenos Aires, Argentina, 1425
- Local Institution - 0043
-
El Palomar, Buenos Aires, Argentina, 1684
- Hospital Nacional Profesor Alejandro Posadas
-
El Palomar, Buenos Aires, Argentina, 1684
- Local Institution - 0049
-
-
-
-
New South Wales
-
Randwick, New South Wales, Australia, 2031
- Local Institution
-
Randwick, New South Wales, Australia, 2031
- Local Institution - 065
-
Westmead, New South Wales, Australia, 2145
- Local Institution
-
Westmead, New South Wales, Australia, 2145
- Local Institution - 069
-
-
Queensland
-
Sth Brisbane, Queensland, Australia, 4101
- Local Institution - 0064
-
Sth Brisbane, Queensland, Australia, 4101
- Local Institution
-
-
South Australia
-
North Adelaide, South Australia, Australia, 5006
- Local Institution
-
North Adelaide, South Australia, Australia, 5006
- Local Institution - 067
-
-
Victoria
-
Parkville, Victoria, Australia, 3052
- Local Institution
-
Parkville, Victoria, Australia, 3052
- Local Institution - 0066
-
-
-
-
-
Campinas, Brazil, 13083-970
- Local Institution - 0020
-
Campinas, Brazil, 13083-970
- Local Institution
-
Sao Paulo, Brazil, 04023-062
- Local Institution
-
Sao Paulo, Brazil, 01401-000
- Local Institution - 0039
-
Sao Paulo, Brazil, 01401-000
- Local Institution
-
-
Parana
-
Curitiba, Parana, Brazil, 80060-900
- Local Institution
-
Curitiba, Parana, Brazil, 80060-900
- Local Institution - 0021
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brazil, 90035-003
- Local Institution
-
Porto Alegre, Rio Grande Do Sul, Brazil, 90035-003
- Local Institution - 0022
-
-
SAO Paulo
-
São Paulo, SAO Paulo, Brazil, 04520-013
- Local Institution - 0019
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Alberta Children's Hospital
-
Calgary, Alberta, Canada, T3B 6A8
- Local Institution - 0079
-
Edmonton, Alberta, Canada, T6G 2B7
- Stollery Children's Hospital
-
Edmonton, Alberta, Canada, T6G 2B7
- Local Institution - 0078
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- BC Children's Hospital
-
Vancouver, British Columbia, Canada, V6H 3V4
- Local Institution - 077
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 6R8
- IWK Health Centre
-
Halifax, Nova Scotia, Canada, B3K 6R8
- Local Institution - 073
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L1
- Children's Hospital of Eastern Ontario
-
Ottawa, Ontario, Canada, K1H 8L1
- Local Institution - 086
-
Toronto, Ontario, Canada, M5G 1X8
- The Hospital for Sick Children
-
Toronto, Ontario, Canada, M5G 1X8
- Local Institution - 076
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1C5
- CHU Ste-Justine
-
Montreal, Quebec, Canada, H3T 1C5
- Local Institution - 080
-
-
-
-
-
Lyon, France, 69008
- Local Institution - 0030
-
Lyon, France, 69008
- Local Institution
-
Nantes, France, 44093
- Local Institution
-
Nantes, France, 44093
- Local Institution - 0032
-
Paris, France, 75012
- Local Institution
-
Paris, France, 75012
- Local Institution - 0037
-
Paris, France, 75935
- Local Institution - 0029
-
Paris, France, 75935
- Local Institution
-
Paris Cedex 12, France, 75571
- Local Institution
-
Poitiers, France, 86000
- Local Institution
-
Poitiers, France, 86000
- Local Institution - 036
-
-
-
-
-
Frankfurt, Germany, 60590
- Local Institution
-
Frankfurt, Germany, 60590
- Local Institution - 075
-
Hannover, Germany, 30625
- Local Institution
-
Hannover, Germany, 30625
- Local Institution - 0074
-
-
-
-
-
Bangalore, India, 560027
- Local Institution - 0088
-
Kolkatta, India, 700 016
- Local Institution - 0082
-
Kolkatta, India, 700 016
- Local Institution
-
Mumbai, India, 400010
- Local Institution - 0085
-
Mumbai, India, 400010
- Local Institution
-
Trivandrum, India, 695011
- Local Institution - 0084
-
Trivandrum, India, 695011
- Local Institution
-
-
Gujarat
-
Navrangpura, Ahmedabad, Gujarat, India, 380009
- Local Institution - 0089
-
Navrangpura, Ahmedabad, Gujarat, India, 380009
- Local Institution
-
-
Karnataka
-
Bangalore, Karnataka, India, 560027
- Local Institution
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400010
- Local Institution
-
Pune, Maharashtra, India, 411001
- Local Institution
-
Pune, Maharashtra, India, 411001
- Local Institution - 0094
-
-
Tamil Nadu
-
Madurai, Tamil Nadu, India, 625107
- Local Institution
-
Madurai, Tamil Nadu, India, 625107
- Local Institution - 0093
-
-
Tamilnadu
-
Vellore, Tamilnadu, India, 632004
- Local Institution
-
-
-
-
-
Bologna, Italy, 40138
- Local Institution
-
Bologna, Italy, 40138
- Local Institution - 038
-
Monza, Italy, 20900
- Local Institution - 006
-
Monza (MB), Italy, 20900
- Local Institution
-
Roma, Italy, 00161
- Local Institution
-
Roma, Italy, 00161
- Local Institution - 070
-
Roma, Italy, 00165
- Local Institution - 0059
-
Roma, Italy, 00165
- Local Institution
-
Torino, Italy, 10126
- Local Institution
-
Torino, Italy, 10126
- Local Institution - 015
-
-
-
-
-
Seoul, Korea, Republic of, 137-701
- Local Institution
-
Seoul, Korea, Republic of, 05505
- Local Institution
-
Seoul, Korea, Republic of, 05505
- Local Institution - 0092
-
Seoul, Korea, Republic of, 137-701
- Local Institution - 0091
-
-
-
-
Distrito Federal
-
Cuauhtémoc, Distrito Federal, Mexico, 06720
- Local Institution - 0051
-
Df, Distrito Federal, Mexico, 06720
- Local Institution
-
Mexico, Distrito Federal, Mexico, 04530
- Local Institution
-
Mexico, Distrito Federal, Mexico, 04530
- Local Institution - 0053
-
Mexico D.f., Distrito Federal, Mexico, 06726
- Local Institution - 0052
-
Mexico D.f., Distrito Federal, Mexico, 06726
- Local Institution
-
Mexico, D. F., Distrito Federal, Mexico, 06726
- Local Institution
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44340
- Hospital Civil De Guadalajara - Nuevo Dr. Juan I. Menchaca
-
Guadalajara, Jalisco, Mexico, 44340
- Local Institution - 0054
-
-
Nuevo Leon
-
Monterrey, Nuevo Leon, Mexico, 64460
- Local Institution
-
Monterrey, Nuevo Leon, Mexico, 64460
- Local Institution - 0050
-
Monterrey, N.l., Nuevo Leon, Mexico, 64180
- Local Institution - 0060
-
Monterrey, N.l., Nuevo Leon, Mexico, 64180
- Local Institution
-
-
-
-
-
Rotterdam, Netherlands, 3015 GJ
- Local Institution - 0007
-
Rotterdam, Netherlands, 3015 GJ
- Local Institution
-
Utrecht, Netherlands, 3584 CS
- Local Institution - 0099
-
-
-
-
-
Bucharest, Romania, 022322
- Local Institution - 0095
-
Bucharest, Romania, 022322
- Local Institution
-
Sector 2, Romania, 022328
- Local Institution - 0097
-
-
-
-
-
Moscow, Russian Federation, 115478
- Local Institution
-
Moscow, Russian Federation, 117198
- Local Institution
-
Moscow, Russian Federation, 115478
- Local Institution - 0017
-
Moscow, Russian Federation, 117198
- Local Institution - 0023
-
Saint-petersburg, Russian Federation, 197022
- Local Institution - 0018
-
Saint-petersburg, Russian Federation, 197022
- Local Institution
-
-
-
-
-
Singapore, Singapore, 119074
- Local Institution - 0071
-
Singapore, Singapore, 119228
- Local Institution
-
-
-
-
FREE State
-
Bloemfontein, FREE State, South Africa, 9301
- Local Institution
-
Bloemfontein, FREE State, South Africa, 9301
- Local Institution - 0055
-
-
Gauteng
-
Pretoria, Gauteng, South Africa, 0001
- Local Institution - 058
-
Pretoria, Gauteng, South Africa, 0001
- Local Institution
-
-
Western CAPE
-
Cape Town, Western CAPE, South Africa, 7925
- Local Institution - 0057
-
Cape Town, Western CAPE, South Africa, 7925
- Local Institution
-
Tygerberg, Western CAPE, South Africa, 7505
- Local Institution - 062
-
Tygerberg, Western CAPE, South Africa, 7505
- Local Institution
-
-
-
-
-
Barcelona, Spain, 08035
- Local Institution
-
Barcelona, Spain, 08025
- Local Institution
-
Barcelona, Spain, 08025
- Local Institution - 0013
-
Barcelona, Spain, 08035
- Local Institution - 0012
-
Madrid, Spain, 28046
- Local Institution
-
Madrid, Spain, 28009
- Local Institution
-
Madrid, Spain, 28009
- Local Institution - 0011
-
Madrid, Spain, 28046
- Local Institution - 0010
-
Malaga, Spain, 29010
- Local Institution
-
Malaga, Spain, 29010
- Local Institution - 0041
-
Valencia, Spain
- Local Institution
-
Valencia, Spain, 46009
- Local Institution
-
Valencia, Spain, 46009
- Local Institution - 0033
-
-
-
-
Central
-
Glasgow, Central, United Kingdom, G3 8SJ
- Local Institution - 0016
-
Glasgow, Central, United Kingdom, G3 8SJ
- Local Institution
-
-
Surrey
-
Sutton, Surrey, United Kingdom, SM2 5PT
- Local Institution
-
Sutton, Surrey, United Kingdom, SM2 5PT
- Local Institution - 0009
-
-
West Midlands
-
Birmingham, West Midlands, United Kingdom, B4 6NH
- Local Institution
-
Birmingham, West Midlands, United Kingdom, B4 6NH
- Local Institution - 0008
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Local Institution
-
-
Arizona
-
Phoenix, Arizona, United States, 85016
- Phoenix Children's Hospital
-
Phoenix, Arizona, United States, 85016
- Local Institution - 0005
-
-
California
-
Long Beach, California, United States, 90801-1428
- Jonathan Jaques Children'S Cancer Center
-
Long Beach, California, United States, 90806
- Jonathan Jaques Children'S Cancer Center
-
Long Beach, California, United States, 90806
- Local Institution - 0001
-
Orange, California, United States, 92868
- Children's Hospital of Orange County
-
Orange, California, United States, 92868
- Local Institution - 0024
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Children's Hospital
-
Aurora, Colorado, United States, 80045
- Local Institution - 0004
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Children's Healthcare of Atlanta - Egleston
-
Atlanta, Georgia, United States, 30322
- Children's Healthcare of Atlanta - Egleston Hospital
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Children's Hospital of Chicago
-
Chicago, Illinois, United States, 60611
- Local Institution
-
Chicago, Illinois, United States, 60611
- Local Institution - 0072
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute.
-
Boston, Massachusetts, United States, 02215
- Dana Faber Cancer Institute
-
Boston, Massachusetts, United States, 02215
- Local Institution - 0040
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Nassau
-
New York, New York, United States, 10016
- Stephen D. Hassenfeld Children'S Center
-
New York, New York, United States, 10021
- Local Institution - 0061
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Local Institution - 0002
-
Portland, Oregon, United States, 97239
- Oregon Health & Sci Univ
-
Portland, Oregon, United States, 97239-3098
- Oregon Health & Sci Univ
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104-4318
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, United States, 19104-4318
- Local Institution - 0014
-
Pittsburgh, Pennsylvania, United States, 15224
- Children's Hospital of Pittsburgh
-
Pittsburgh, Pennsylvania, United States, 15224
- Local Institution - 0003
-
-
Texas
-
Houston, Texas, United States, 77030
- Local Institution - 0048
-
Houston, Texas, United States, 77030-4009
- MD Anderson Cancer Center
-
Houston, Texas, United States, 77030
- Texas Children's Cancer Center
-
Houston, Texas, United States, 77030-4009
- Local Institution - 0035
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children's
-
Seattle, Washington, United States, 98105
- Local Institution - 0028
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
Inclusion Criteria:
- CP-CML who prove resistant or intolerant to imatinib (Cohort 1)
- Ph+ ALL, AP-CML, or BP-CML who are resistant or intolerant to or who relapse after imatinib therapy (Cohort 2)
- Newly diagnosed, treatment naive CP-CML (Cohort 3)
- Lansky or Karnofsky scale >50
- Life expectancy ≥12 weeks
- Adequate hepatic and renal function
- Written informed consent
- Target Population for the PK substudy must obtain written informed consent from subject, or from parents or legal guardians for minor subjects, according to local law and regulation
- Target Population for the PK substudy subjects must have CP-CML and be taking daily dasatinib (tablets or PFOS) either as part of Cohort 1 or Cohort 3 of this protocol. Patients receiving commercial dasatinib tablets outside of this protocol may be invited to participate in this PK substudy
- Target Population for the PK substudy subjects with CP-CML who are tolerating dasatinib tablet dose of at least 60 mg/m2 or dasatinib PFOS dose of at least 72 mg/m2
- Target Population for the PK substudy prior exposure to imatinib or other TKI therapy is permissible
- Target Population for the PK substudy subjects must meet relevant inclusion criteria
Exclusion Criteria:
- Eligibility for potentially-curative therapy including hematopoietic stem-cell transplantation
- Symptomatic CNS involvement (other than signs and symptoms caused by leptomeningeal disease)
- Isolated extramedullary disease
- Prior therapy with Dasatinib
- Target Population for the PK substudy subjects participating in the PK substudy must comply with the relevant exclusion criteria
- Target Population for the PK substudy subjects are not allowed to use proton pump inhibitors, H2 antagonists, CYP3A4 inhibitors and inducers when entering the PK substudy
Other inclusion/exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1: Imatinib-resistant/intolerant CP-CML
Dasatinib 60 mg/m² tablet every day (QD) [with a maximum dose of 100 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit OR Dasatinib 72 mg/m² powder for oral suspension (PFOS) QD [with a maximum dose of 120 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit |
Other Names:
|
Experimental: Cohort 2: Ph+ALL or AP- or BP-CML
Dasatinib 80 mg/m² tablet QD [with a maximum dose of 140 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit OR Dasatinib 96 mg/m² PFOS QD [with a maximum dose of 170 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit |
Other Names:
|
Experimental: Cohort 3: Newly diagnosed, treatment naïve CP-CML
Dasatinib 60 mg/m² tablet QD [with a maximum dose of 100 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit OR Dasatinib 72 mg/m² PFOS QD [with a maximum dose of 120 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit |
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major Cytogenetic Response (MCyR) Rate
Time Frame: From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)
|
Major Cytogenetic Response (MCyR) rate is defined as the proportion of all treated participants who achieved a complete (0%) or partial (1%-35% Ph+ metaphases in at least 20 metaphases in bone marrow) cytogenetic response, expressed as percentage.
The denominator of the MCyR response rate consists of all treated participants in Cohort 1, and the numerator is all participants in Cohort 1 achieving MCyR.
95% confidence interval was calculated by Clopper-Pearson exact method.
|
From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)
|
Complete Hematologic Response (CHR) Rate
Time Frame: From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)
|
Complete Hematologic Response (CHR) rate is defined as the proportion of all treated participants who achieve a confirmed CHR while on-study, expressed as percentage.
CHR is defined as including no more than 5% blasts in bone marrow and normal white blood cell count without blasts in peripheral blood, expressed as percentage.
The denominator of the CHR response rate consists of all treated participants in Cohort 2, and the numerator is all participants in Cohort 2 achieving CHR.
95% confidence interval was calculated by Clopper-Pearson exact method.
|
From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)
|
Complete Cytogenetic Response (CCyR) Rate
Time Frame: From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)
|
Complete Cytogenetic Response (CCyR) rate is defined as the proportion of all treated participants who achieve a CCyR while on-study, expressed as a percentage.
CCyR rate is defined as 0% Ph+ metaphases in at least 20 metaphases in bone marrow.
The denominator of the CCyR response rate consists of all treated participants in Cohort 3, and the numerator is all participants in Cohort 3 achieving CCyR.
95% confidence interval was calculated by Clopper-Pearson exact method.
|
From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major Cytogenetic Response (MCyR) Rate in Cohort 2
Time Frame: From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)
|
Major Cytogenetic Response (MCyR) rate was defined as the proportion of all treated participants who achieved a complete (0%) or partial (1%-35% Ph+ metaphases in at least 20 metaphases in bone marrow) cytogenetic response.
The percentage of treated participants in each arm with MCyR is reported.
|
From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)
|
Complete Hematologic Response (CHR) Rate in Cohorts 1 and 3
Time Frame: From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)
|
Complete Hematologic Response (CHR) rate defined as the proportion of all treated participants who achieve a confirmed CHR while on-study.
CHR is defined as including no more than 5% blasts in bone marrow and normal white blood cell count without blasts in peripheral blood.
The percentage of treated participants in each arm with CHR is reported.
|
From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)
|
Rate of Best Cytogenetic Response
Time Frame: From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)
|
The number of participants achieving their best on-study cytogenetic response was reported as a percentage of all treated participants in that arm.
(Based on >=20 Metaphases)
|
From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)
|
Time to Major Cytogenetic Response (MCyR)
Time Frame: From first dose until MCyR criteria are met (assessed up to September 2016, approximately 90 months)
|
Time to MCyR is defined as the time from first dose of dasatinib until the first day MCyR criteria are met, computed only for participants whose best response is MCyR.
(Based on >=20 Metaphases)
|
From first dose until MCyR criteria are met (assessed up to September 2016, approximately 90 months)
|
Duration of Major Cytogenetic Response (MCyR)
Time Frame: From first day criteria are met for MCyR until the date PD is reported or death (assessed up to September 2016, approximately 90 months)
|
Duration of MCyR will be computed from the first day criteria are met for MCyR until the date progressive disease (PD) is reported (or treatment is discontinued for PD) or death.
Participants who neither discontinue due to PD nor die will be censored on the date of their last hematologic or cytogenetic assessment, whichever comes last.
(Based on >=20 Metaphases)
|
From first day criteria are met for MCyR until the date PD is reported or death (assessed up to September 2016, approximately 90 months)
|
Time to Complete Cytogenetic Response (CCyR)
Time Frame: From first dose until CCyR criteria are met, assessed up to September 2016 (approximately 90 months)
|
Time to CCyR is defined as the time from first dose of dasatinib until the first day CCyR criteria are met, computed only for participants whose best response is CCyR.
(Based on >=20 Metaphases)
|
From first dose until CCyR criteria are met, assessed up to September 2016 (approximately 90 months)
|
Duration of Complete Cytogenetic Response (CCyR)
Time Frame: From first day criteria are met for CCyR until the date of progressive disease or death (assessed up to September 2016, approximately 90 months)
|
Duration of CCyR will be computed from the first day criteria are met for CCyR until the date progressive disease (PD) is reported (or treatment is discontinued for PD) or death.
Participants who neither discontinue due to PD nor die will be censored on the date of their last hematologic or cytogenetic assessment, whichever comes last.
(Based on >=20 Metaphases)
|
From first day criteria are met for CCyR until the date of progressive disease or death (assessed up to September 2016, approximately 90 months)
|
Progression-Free Survival (PFS) Rate at 2 Years
Time Frame: 2 years
|
PFS is defined as time from the first dosing date until the time PD is first documented by the investigator or death.
Participants who die without a reported date of progression will be considered to have progressed on the date of death.
Participants who neither progress nor die will be censored on the date of their last cytogenetic or hematologic assessment.
The percentages of progression-free participants at 2 years are based on Kaplan-Meier estimation.
Disease Progression was defined as any of the following criteria: -For CP-CML, progression to AP-CML or BP-CML while at highest tolerated dose -Increasing WBC -Loss of CHR (defined as any of the following: WBC count rises to >20.0x10^9/L; Platelet count rises to >600x10^9/L; appearance of extramedullary disease; appearance of >5% myelocytes+metamyelocytes in blood; appearance of blasts/promyelocytes in peripheral blood) -Loss of MCyR or increase in Ph+ bone marrow cells by >=30% from nadir -Death from any case during treatment
|
2 years
|
Time to Complete Hematologic Response (CHR)
Time Frame: From first dose until CHR criteria are met, assessed up to September 2016 (approximately 90 months)
|
Time to CHR is defined as the time from first dose of dasatinib until the first day CHR criteria are met, provided they are confirmed 4 weeks later, computed only for participants whose best response is CHR.
|
From first dose until CHR criteria are met, assessed up to September 2016 (approximately 90 months)
|
Duration of Complete Hemotologic Response (CHR)
Time Frame: From first day criteria are met for CHR until date of disease progression or death (assessed up to September 2016, approximately 90 months)
|
Duration of CHR will be computed from the first day all criteria are met for CHR, provided they are confirmed 4 weeks later, until the date progressive disease (PD) is reported (or treatment is discontinued for PD) or death.
Participants who neither discontinue due to PD nor die will be censored on the date of their last hematologic assessment.
|
From first day criteria are met for CHR until date of disease progression or death (assessed up to September 2016, approximately 90 months)
|
Disease-Free Survival Rate at 2 Years
Time Frame: 2 years
|
Disease free survival is defined as time from CCyR for participants with newly diagnosed chronic phase CML and for participants with chronic phase CML who are resistant or intolerant to imatinib (cohort 3 and cohort 1), and as time from CHR for participants with advanced phase CML and PH + ALL (cohort 2) until the time progression is first documented by the investigator or death from any cause.
The percentages of disease-free participants at 2 years are based on Kaplan-Meier estimation.
(CML: Chronic Myeloid Leukemia)
|
2 years
|
Overall Survival (OS) Rate at 2 Years
Time Frame: 2 years
|
OS is defined as time from the first dosing date until the time of death.
All participants will be followed yearly for survival for up to 5 years after treatment discontinuation.
Participants who have not died or who are lost to follow-up will be censored on the last date the participant is known to be alive.
The percentages of surviving participants at 2 years are based on Kaplan-Meier estimation.
|
2 years
|
Major Molecular Response (MMR) Rate
Time Frame: From date of first treatment to date of MMR (assessed up to September 2016, approximately 90 months)
|
Molecular response was assessed using BCR-ABL transcript levels measurement by real-time quantitative polymerase chain reaction (qPCR).
MMR for participants with the p210 BCR-ABL transcript variant was defined as a ratio BCR-ABL/ABL <= 10-3 or 0.1% on the international scale.
In this study, ABL was used as the control-gene.
For a participant with the p190 BCR-ABL transcript variant (occurring in Cohort 2 only), on-study assessments were compared to the participant's individual baseline BCR-ABL/ABL ratio and a reduction to < 0.1% or a 3-log reduction from baseline was considered an MMR.
|
From date of first treatment to date of MMR (assessed up to September 2016, approximately 90 months)
|
Complete Molecular Response (CMR) Rate
Time Frame: From date of first treatment to date of CMR (assessed up to September 2016, approximately 90 months)
|
Molecular response was assessed using BCR-ABL transcript levels measurement by real-time quantitative polymerase chain reaction (qPCR).
(CMR) is defined as absence of BCR-ABL rearrangements by real-time qPCR analysis.
The percentage of treated participants with CMR is reported by arm.
|
From date of first treatment to date of CMR (assessed up to September 2016, approximately 90 months)
|
Major Cytogenetic Response (MCyR) Rate up to 2 Years
Time Frame: 24 months
|
Major Cytogenetic Response (MCyR) rate is defined as the proportion of all treated participants who achieved a complete (0%) or partial (1%-35% Ph+ metaphases in at least 20 metaphases in bone marrow) cytogenetic response.
The percentage of treated participants with MCyR is reported by arm.
|
24 months
|
Complete Cytogenetic Response (CCyR) Rate up to 2 Years
Time Frame: 24 months
|
Complete Cytogenetic Response (CCyR) rate is defined as the proportion of all treated participants who achieve a CCyR while on-study.
CCyR rate is defined as 0% Ph+ metaphases in at least 20 metaphases in bone marrow.
The percentage of treated participants with CCyR is reported by arm.
|
24 months
|
Major Molecular Response (MMR) Rate up to 2 Years
Time Frame: 24 months
|
Molecular response will be assessed using BCR-ABL transcript levels measurement by real-time qPCR.
MMR for participants with the p210 BCR-ABL transcript variant is defined according to the recommendations of Hughes et al. as a ratio BCR-ABL/ABL <= 10-3 or 0.1% on the international scale proposed by the authors.
The standardized baseline, as established in the IRIS trial, is taken to represent 100% on the international scale and a 3-log reduction in ratio (BCR-ABL transcripts/ABL or BCR) from the standardized baseline (MMR) is fixed at 0.1%.
In this study, ABL or other housekeeping gene, will be used as the control-gene.
For a participant with the p190 BCR-ABL transcript variant, on-study assessments will be compared to the participant's individual baseline BCR-ABL/ABL ratio and a reduction to < 0.1% or a 3-log reduction from baseline will be considered an MMR.
The percentage of treated participants with MMR is reported by arm.
|
24 months
|
Complete Molecular Response (CMR) Rate up to 2 Years
Time Frame: 24 months
|
Molecular response will be assessed using BCR-ABL transcript levels measurement by real-time quantitative polymerase chain reaction (qPCR).
(CMR) is defined as absence of BCR-ABL rearrangements by real-time qPCR analysis.
The percentage of treated participants with CMR is reported by arm.
|
24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Disease Attributes
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Chronic Disease
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Chronic-Phase
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Dasatinib
Other Study ID Numbers
- CA180-226
- 2008-002260-33 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia
-
Stanford UniversityTerminatedLeukemia | Leukemia, Lymphocytic, Acute | Leukemia Acute Promyelocytic Leukemia (APL) | Leukemia Acute Lymphoid Leukemia (ALL) | Leukemia Chronic Myelogenous Leukemia (CML) | Leukemia Acute Myeloid Leukemia (AML) | Leukemia Chronic Lymphocytic Leukemia (CLL)United States
-
Massachusetts General HospitalCelgene CorporationTerminatedAcute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic LeukemiaUnited States
-
Institute of Hematology & Blood Diseases HospitalBejing Institute for Stem Cell and Regenerative Medicine; Institute for Stem...RecruitingRefractory Leukemia | Relapsed Leukemia | Acute Myeloid Leukemia, ChildhoodChina
-
Betta Pharmaceuticals Co., Ltd.Not yet recruitingAcute Myeloid Leukemia LeukemiaChina
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States
-
Hybrigenics CorporationUnknownAcute Myelogenous LeukemiaUnited States, France
-
Center for International Blood and Marrow Transplant...National Marrow Donor Program; St. Baldrick's FoundationActive, not recruitingAcute Myelogenous LeukemiaUnited States
-
Massachusetts General HospitalCompleted
-
Beijing Boren HospitalRecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapse LeukemiaChina
-
Kinex Pharmaceuticals Inc.CompletedAcute Myelogenous LeukemiaUnited States
Clinical Trials on Dasatinib
-
Bristol-Myers SquibbCompletedPharmacokinetic Study in Healthy ParticipantsUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Completed
-
Hyoung Jin KangNot yet recruitingAcute Lymphoblastic Leukemia, Pediatric
-
National Cancer Institute (NCI)WithdrawnHematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell MyelomaUnited States
-
National Cancer Institute (NCI)NRG OncologyTerminatedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Recurrent Uterine Corpus CancerUnited States
-
Xspray Pharma ABQPS Bioserve India Pvt LimitedCompleted
-
Peking University Cancer Hospital & InstituteUnknownGastrointestinal Stromal TumorChina
-
Kanto CML Study GroupUnknownMyelogenous Leukemia, Chronic, Chronic PhaseJapan
-
Jonsson Comprehensive Cancer CenterBristol-Myers SquibbCompleted
-
Swiss Group for Clinical Cancer ResearchCompletedGastrointestinal Stromal TumorFrance, Switzerland, Germany, Finland